Video

High-Risk Non-Muscle Invasive Bladder Cancer VL

Search

SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden Details Zach Klaassen interviews Michiel Van der Heijden about the SunRISe-1 trial, which evaluates TAR-200 with or without cetrelimab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Dr. Van der Heijden discusses the trial design and results, highlighting TAR-200 monotherapy's impressive complete response rate of 83.5% and 12-month complete response rate of 57%. He emphasizes the favorab...
Novel Therapies for Non-Muscle Invasive Bladder Cancer: Expert Review - Felix Guerrero-Ramos Details Ashish Kamat interviews Felix Guerrero-Ramos about a European Urology Oncology review on novel treatments for non-muscle-invasive bladder cancer (NMIBC). Dr. Guerrero-Ramos presents an overview of emerging therapies across different risk categories of NMIBC, focusing on intravesical and systemic approaches. He highlights FDA-approved treatments for BCG-unresponsive disease and ongoing trials for B...
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore Details Ashish Kamat hosts a discussion with Matt Galsky and Neal Shore on the latest advancements in bladder cancer treatment, focusing on immunotherapy for advanced bladder cancer and the associated survival benefits. He emphasizes the importance of recognizing and managing immune-related toxicities. Dr. Shore discusses the application of immunotherapy in earlier stages of disease, mentioning pembrolizu...
Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram Details Ashish Kamat is joined by Gautam Jayram to unravel the complexities of BCG unresponsiveness in bladder cancer treatment. Dr. Jayram emphasizes the importance of understanding what constitutes adequate BCG treatment, highlighting the necessity of more than just six initial doses for accurate classification of BCG unresponsiveness. He sheds light on the challenges and disparities in BCG access, part...
Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore Details Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity of...